Biocon insulin capacity expansion and biosimilar launches support margin-led earnings growth

Investment View and Recommendation

Axis Securities’ September 19, 2026 Pick of the Week report presents a positive view on Biocon Ltd, supported by expanding insulin manufacturing capacity, improving profitability and a broad biosimilars and generics product mix.

Recommendation: BUY with a target price of Rs 424, implying 10 per cent upside from the CMP of Rs 385 as of September 18, 2026. The indicated investment horizon is six to nine months.

Insulin Capacity Expansion

A central operating catalyst is the European Medicines Agency approval for the second drug product line at Biocon’s Malaysia insulin facility. According to Axis Securities, the approval effectively doubles manufacturing capacity, with commercial supplies expected to commence from Q2 FY27.

The broker expects utilisation to scale as Biocon also invests in fermentation and peptide platforms to address global demand. Expanding insulin capacity is an important component of the expected growth outlook.

Operating Leverage and Balance-Sheet Improvement

Axis Securities highlights operational synergies across Biocon’s biopharma operations, which are driving operating-expense rationalisation and fiscal discipline. The biosimilars business generated an EBITDA margin of 25 per cent, in line with mid-20s guidance, and the broker expects margin acceleration in H2 FY27.

Structured-debt retirement reduced interest expense by 23 per cent year on year and 8 per cent quarter on quarter to Rs 213 crore. Axis Securities views the lower interest burden as supportive of free cash flow, which Biocon is prioritising for further balance-sheet deleveraging.

Product and Therapeutic Diversification

Biocon operates across oncology, ophthalmology, bone health and diabetes care. Recent launches and product developments include:

• bAflibercept: Marketed as Yesafili in the United States and Malaysia.
• bDenosumab: Marketed as Bosaya and Okelso in North America and Europe.
• Insulin Glargine: Continued market-share gains.
• Insulin Aspart: Expanded payer coverage for the product marketed as Kirsty.
• Generic Liraglutide: Expected global expansion is expected to support GLP-1 growth.

Axis Securities identifies bAspart, bDenosumab, GLP-1 and CalRx insulin partnerships as key catalysts.

Financial Outlook

Axis Securities’ financial summary and estimates are as follows:

Valuation Framework and Outlook

Axis Securities values Biocon using a sum-of-the-parts methodology and assigns higher multiples to the faster-growing biosimilars segment. The broker’s outlook rests on a simplified balance sheet, tapering capital expenditure, expanding insulin capacity, operating leverage and reduced interest costs.

Risks and Disclosures

The report does not provide a separate company-specific risk-factor discussion or a detailed sum-of-the-parts valuation breakdown.